Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Dianne S Hirsch & Wen Jin Wu. (2007) Cdc42: an effector and regulator of ErbB1 as a strategic target in breast cancer therapy. Expert Review of Anticancer Therapy 7:2, pages 147-157.
Read now
Read now
Ladislav Novotny & Thomas Szekeres. (2005) Recent developments in cancer chemotherapy oriented towards new targets. Expert Opinion on Therapeutic Targets 9:2, pages 343-357.
Read now
Read now
Chia-Yu Huang & Laura Rokosz. (2004) Farnesyltransferase inhibitors: recent advances. Expert Opinion on Therapeutic Patents 14:2, pages 175-186.
Read now
Read now
Articles from other publishers (16)
Sven Dänicke, Julia Krenz, Christian Seyboldt, Heinrich Neubauer, Jana Frahm, Susanne Kersten, Karsten Meyer, Janine Saltzmann, Wolfram Richardt, Gerhard Breves, Helga Sauerwein, Michael Sulyok, Ulrich Meyer & Lutz Geue. (2020) Maize and Grass Silage Feeding to Dairy Cows Combined with Different Concentrate Feed Proportions with a Special Focus on Mycotoxins, Shiga Toxin (stx)-Forming Escherichia coli and Clostridium botulinum Neurotoxin (BoNT) Genes: Implications for Animal Health and Food Safety. Dairy 1:2, pages 91-125.
Crossref
Crossref
Jie Lu, Kohei Yoshimura, Koichi Goto, Craig Lee, Ken Hamura, Ohyun Kwon & Fuyuhiko Tamanoi. (2015) Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells. PLOS ONE 10:9, pages e0137595.
Crossref
Crossref
Katja Kohring, Jochen Wiesner, Mirko Altenkämper, Jacek Sakowski, Katrin Silber, Alexander Hillebrecht, Peter Haebel, Hans-Martin Dahse, Regina Ortmann, Hassan Jomaa, Gerhard Klebe & Martin Schlitzer. (2008) Development of Benzophenone-Based Farnesyltransferase Inhibitors as Novel Antimalarials. ChemMedChem 3:8, pages 1217-1231.
Crossref
Crossref
. (2008) Antitumor Activity of LB42907, a Potent and Selective Farnesyltransferase Inhibitor: Synergistic Effect in Combination with Other Anticancer Drugs. Bulletin of the Korean Chemical Society 29:7, pages 1303-1310.
Crossref
Crossref
Yao-Wen Wu, Kirill Alexandrov & Luc Brunsveld. (2007) Synthesis of a fluorescent analogue of geranylgeranyl pyrophosphate and its use in a high-throughput fluorometric assay for Rab geranylgeranyltransferase. Nature Protocols 2:11, pages 2704-2711.
Crossref
Crossref
Lesley-Ann Martin, Julia E. Head, Sunil Pancholi, Janine Salter, Emma Quinn, Simone Detre, Stan Kaye, Angela Howes, Mitch Dowsett & Stephen R.D. Johnston. (2007)
The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression
in vitro
and
in vivo
. Molecular Cancer Therapeutics 6:9, pages 2458-2467.
Crossref
Crossref
David Michod & Christian Widmann. (2007) DNA-damage sensitizers: Potential new therapeutical tools to improve chemotherapy. Critical Reviews in Oncology/Hematology 63:2, pages 160-171.
Crossref
Crossref
Yao-Wen Wu, Herbert Waldmann, Reinhard Reents, Frank H. Ebetino, Roger S. Goody & Kirill Alexandrov. (2006) A Protein Fluorescence Amplifier: Continuous Fluorometric Assay for Rab Geranylgeranyltransferase. ChemBioChem 7:12, pages 1859-1861.
Crossref
Crossref
Xiaohua Xue, Kuei-Tai A. Lai, Jing-Feng Huang, Yin Gu, Lars Karlsson & Anne Fourie. (2006) Anti-Inflammatory Activity in Vitro and in Vivo of the Protein Farnesyltransferase Inhibitor Tipifarnib. Journal of Pharmacology and Experimental Therapeutics 317:1, pages 53-60.
Crossref
Crossref
C.T. Thomas, A. Ammar, J.J. Farrell & H. Elsaleh. (2006) Radiation Modifiers: Treatment Overview and Future Investigations. Hematology/Oncology Clinics of North America 20:1, pages 119-139.
Crossref
Crossref
Chia-Yu Huang, Tara M. Stauffer, Corey L. Strickland, John C. Reader, He Huang, Ge Li, Alan B. Cooper, Ronald J. Doll, Ashit K. Ganguly, John J. Baldwin & Laura L. Rokosz. (2006) Guiding farnesyltransferase inhibitors from an ECLiPS® library to the catalytic zinc. Bioorganic & Medicinal Chemistry Letters 16:3, pages 507-511.
Crossref
Crossref
Laura L. Rokosz, Chia-Yu Huang, John C. Reader, Tara M. Stauffer, Daniel Chelsky, Nolan H. Sigal, Ashit K. Ganguly & John J. Baldwin. (2005) Surfing the piperazine core of tricyclic farnesyltransferase inhibitors. Bioorganic & Medicinal Chemistry Letters 15:24, pages 5537-5543.
Crossref
Crossref
Mark R. Lackner, Rachel M. Kindt, Pamela M. Carroll, Katherine Brown, Michael R. Cancilla, Changyou Chen, Heshani de Silva, Yvonne Franke, Bo Guan, Tim Heuer, Tak Hung, Kevin Keegan, Jae Moon Lee, Veeraswamy Manne, Carol O’Brien, Dianne Parry, Juan J. Perez-Villar, Rajashekar K. Reddy, Hong Xiao, Hangjun Zhan, Mark Cockett, Greg Plowman, Kevin Fitzgerald, Michael Costa & Petra Ross-Macdonald. (2005) Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. Cancer Cell 7:4, pages 325-336.
Crossref
Crossref
Katharine Walker & Michael F Olson. (2005) Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Current Opinion in Genetics & Development 15:1, pages 62-68.
Crossref
Crossref
Julia Head & Stephen RD Johnston. (2004) New targets for therapy in breast cancer: Farnesyltransferase inhibitors. Breast Cancer Research 6:6.
Crossref
Crossref
Mark F. McCarty. (2016) Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy. Integrative Cancer Therapies 3:4, pages 349-380.
Crossref
Crossref